Manufacturers: Act now on UK MDR 2002 Part 4A and 2025 amendment

Placing a medical device on the Great Britain market means conforming to the UK MDR 2002, registering it with the MHRA, and knowing exactly where you sit on the CE‑to‑UKCA transition timeline. Manufacturers must already have post‑market surveillance systems running under the 2024 Part 4A amendment. Miss any one of these three and the device has no lawful route to market.

TL;DR:

• Devices must be registered with the MHRA, have UKCA marking or transitional CE marking valid until at least June 2030, and maintain active post-market surveillance.
• Classification determines whether devices can be self-declared or require UK approved body certification, with higher-risk categories needing separate UKCA approval.
• Manufacturers need to update their technical files continuously, especially after changes or corrective actions, and should start engagement with UK approved bodies early to avoid delays.
• Ongoing post-market surveillance under the 2024 Part 4A amendment requires building proactive systems that generate real data, not just policies, to meet legal compliance.
• Suppliers must provide traceable batch certificates and notify manufacturers of any process changes to ensure technical documentation remains compliant during UKCA certification.

Table of Contents

• What are the essential UK MDR 2002 legal requirements?
• What is the UK MDR 2002 and how is it structured?
• Who counts as a manufacturer under UK MDR 2002, and how do you register?
• How does device classification determine your conformity route?
• What changed under the new Part 4A post-market surveillance rules?
• How do custom-made devices and special categories differ?
• What technical documentation and clinical evidence do you need?
• What’s a realistic compliance timeline for market entry?
• How do you keep your registration and compliance current?
• How should component suppliers support OEM compliance?
• How Precision Glasses supports your technical file preparation
• Sources

What are the essential UK MDR 2002 legal requirements?

Every device placed on the Great Britain market has to clear three hurdles before it reaches a customer: registration, conformity evidence, and an active surveillance system. None of these are optional extras bolted onto “real” compliance work. They are the compliance work.

• Registration with the MHRA covers general medical devices, in vitro diagnostics (IVDs), and custom-made devices alike, before any of them reaches the GB market.
• Marking and conformity evidence currently accepts CE marking on a transitional basis, but CE‑marked devices are accepted only until 30 June 2030 at the latest for certain device types, with UKCA becoming the long-term standard.
• UK approved bodies step in wherever a device can’t be self‑declared, covering higher‑risk classes and specific IVD categories.
• Post-market surveillance is now a distinct statutory duty, not a best‑practice add‑on, following the 2024 amendment.

Pro Tip: Don’t treat the 2030 CE deadline as a single fixed date. It varies by device type and risk class, so check your specific product category against the current GOV.UK position rather than assuming a blanket cut-off.

The regulatory shift that catches manufacturers off guard is the fourth point. Regulators have moved from pre-market gatekeeping toward continuous lifecycle oversight, which means a device that cleared conformity assessment two years ago can still fall foul of the rules today if surveillance isn’t running properly.

What is the UK MDR 2002 and how is it structured?

The Medical Devices Regulations 2002 (SI 2002/618, as amended) is the primary legal instrument governing medical devices in the UK, and it’s worth reading in its consolidated form rather than relying on secondary summaries. The legislation.gov.uk version reflects every amendment made since the original statutory instrument, including the 2024 and 2025 changes discussed later.

The regulation splits obligations by device type. Part II covers general medical devices, Part III governs active implantable devices, and Part IV sets out requirements for in vitro diagnostic devices, with each Part attaching different classification rules, conformity routes, and documentation expectations. Part V then addresses UK approved bodies and marking, which is where the practical UKCA mechanics live.

Schedules attached to the instrument do a lot of the technical heavy lifting:

• Schedules adapt what were originally EU annex requirements into UK-specific essential requirements, covering things like general safety and performance obligations.
• Modifications to these schedules (including provisions sometimes referred to under headings like Schedule 2A) exist specifically to decouple UK obligations from EU annexes that no longer apply directly in Great Britain.
• Reading the schedule relevant to your device’s Part is usually more useful than reading the regulation front to back, since most of your compliance detail sits there rather than in the main body text.

Regulatory teams who skip the schedules and rely on GOV.UK summaries alone often miss nuance that only shows up in the statutory text itself.

Who counts as a manufacturer under UK MDR 2002, and how do you register?

The regulation assigns distinct legal duties to different actors in the supply chain, and getting these roles wrong is one of the more common early-stage mistakes we see manufacturers make.

1. The manufacturer designs, produces, and takes ultimate responsibility for the device’s conformity, regardless of who physically assembles it.
2. The authorised representative (where a manufacturer is based outside the UK) acts on the manufacturer’s behalf for regulatory purposes within Great Britain.
3. The UK responsible person performs a similar function specifically for the UK market, and non-UK manufacturers without a UK presence generally need to appoint one before registering.
4. Registration itself happens through the MHRA, and it is required to register devices before placing them on the Great Britain market, covering general devices, IVDs, and custom-made devices.
5. Ongoing updates are a separate duty from initial registration. Regulations including regs 7A, 19, 21A/21B, 33A and 44 specify when manufacturers must notify the MHRA of changes, and manufacturers often underestimate this ongoing obligation, treating registration as a one-off task rather than a living record.

Northern Ireland sits under a different arrangement because of the Northern Ireland Protocol, which keeps NI aligned more closely with EU device rules than the rest of Great Britain. A manufacturer selling into both GB and NI often needs to run parallel compliance tracks rather than assuming one registration covers the whole of the UK. If your distribution touches Northern Ireland, check the specific NI guidance separately rather than extrapolating from GB rules.

How does device classification determine your conformity route?

Classification decides everything downstream, from which Part of the regulation applies to whether you need a UK approved body at all. Class I devices that are non-sterile and have no measurement function, along with general IVDs, can be self-declared by the manufacturer alone. Class IIa, IIb, and III devices cannot. Neither can Class I devices that happen to be sterile or carry a measurement function, which is a distinction manufacturers sometimes miss when they assume “Class I” automatically means “self-declare.”

Here’s the practical breakdown:

• Self-declaration route: Class I (non-sterile, non-measuring) general devices and general IVDs. No external body involvement required, though technical documentation still has to exist and stand up to scrutiny.
• UK approved body route: Class IIa, IIb, III devices; sterile or measurement-function Class I devices; and specific IVD categories that carry higher risk profiles.
• Approved body limits: a UK approved body assesses conformity against UK MDR 2002 and can issue UKCA certification, but it cannot issue CE certificates. That distinction matters for anyone assuming one certification process covers both markets.

Pro Tip: If your device already holds a CE certificate from an EU notified body, that certificate doesn’t transfer into UKCA territory. You need separate engagement with a UK approved body for UKCA, even where the technical file overlaps almost entirely.

This is where dual-track compliance becomes a genuine operational cost rather than a theoretical concern. Manufacturers selling into both GB and EU markets typically need to run parallel technical-file management, engage separate approved bodies for each certification, and maintain tight change control so a design update doesn’t accidentally invalidate one certificate while leaving the other untouched. Given that CE acceptance in Great Britain has transitional end points for device types, varying by classification and legislation, planning your UKCA transition now, rather than waiting for the deadline to bite, avoids a scramble later. Our guide to UKCA marking compliance walks through the documentation an approved body will expect from your supply chain during that transition.

What changed under the new Part 4A post-market surveillance rules?

Manufacturers no longer get to treat post-market surveillance as a discretionary quality-improvement activity. The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 inserted mandatory post-market surveillance duties into the UK MDR 2002, creating explicit statutory duties around incident notification and corrective action that didn’t exist in the same form before.

The practical shift is significant. MHRA’s addition of these requirements signals a move toward lifecycle oversight rather than pre-market scrutiny alone, which means the compliance workload doesn’t end once a device clears conformity assessment. It continues for as long as the device stays on the market.

To meet Part 4A obligations, manufacturers typically need to:

1. Build or formalise a PMS system that actively monitors device performance in the field, not just responds to complaints as they arrive.
2. Run trend analysis on incident data so patterns emerge before they become serious safety signals.
3. Document corrective and preventive actions with a clear audit trail linking each action back to the surveillance finding that triggered it.
4. Report serious incidents to the MHRA within the timelines the regulations specify, rather than folding them into routine internal reviews.
5. Update your quality management system and supplier agreements so PMS data flows in from every stage of the supply chain, not just from direct customer feedback.

The manufacturers struggling most with Part 4A tend to be ones that had a PMS process on paper but never wired it into their actual QMS workflow. A surveillance system that exists only in a policy document doesn’t satisfy the regulation. It has to generate real, traceable data.

How do custom-made devices and special categories differ?

Not every device follows the standard conformity path, and treating a custom-made or special-category device as though it does create avoidable compliance gaps.

• Custom-made devices still require registration and documentation, even though they’re produced to an individual specification rather than mass-manufactured. A custom-made device statement typically needs to identify the device, confirm it was made to a specific practitioner’s design, and record the intended patient or user.
• IVD list categories (List A, List B, and self-test devices) carry their own conformity implications, with List A generally attracting the most stringent approved-body involvement because of the public health risk if results are wrong.
• Sterile or measurement-function Class I devices fall outside standard Class I self-declaration, requiring UK approved body input even though a “normal” Class I device wouldn’t need it.
• Active implantable devices sit under Part III specifically, with conformity and labelling requirements distinct from Part II general devices, reflecting the higher stakes of a permanently implanted product.

If your product touches any of these categories, don’t assume the general classification rules apply cleanly. Check the specific provision for your category before finalising your conformity route.

What technical documentation and clinical evidence do you need?

The technical file is what an MHRA inspector or approved body auditor will actually ask to see, so it needs to hold up under scrutiny rather than exist as a compliance formality.

A complete file should cover:

• Device description and intended purpose, stated precisely enough that classification and conformity route are unambiguous.
• Design control records, showing how the device moved from specification to finished product.
• Risk management documentation, ideally following a recognised risk management process rather than an ad hoc assessment.
• Manufacturing evidence, including process controls and quality checks applied during production.
• Labelling and instructions for use, matching whatever marking regime (UKCA, or CE within the transitional window) applies to that specific device.

Clinical evaluation requirements scale with risk class. A low-risk Class I device generally needs less clinical evidence than a Class III implant, but post-market data increasingly strengthens weaker pre-market evidence across all classes, particularly now that PMS obligations under Part 4A generate more field data to draw on.

Pro Tip: Treat your technical file as a living document from day one, not something you finish once and archive. Every corrective action, design change, or supplier substitution should trigger a file update, because an outdated technical file is one of the first things an approved body flags during reassessment.

Record-keeping duration matters too. Files need to remain accessible and current for as long as the device stays on the market, plus a retention period afterwards, and that retention clock resets in practice every time you make a material change.

What’s a realistic compliance timeline for market entry?

Turning these obligations into a working project plan means sequencing the steps in the right order and assigning clear ownership before work starts.

1. Classify the device against Parts II to IV and confirm whether it’s sterile, has a measurement function, or falls into a special category.
2. Select the conformity route, self-declaration or UK approved body, based on that classification.
3. Prepare the technical file, including risk management and clinical evidence proportionate to the device’s risk class.
4. Engage a UK approved body early if your classification requires one, since approved-body capacity is a common bottleneck manufacturers underestimate.
5. Register the device with the MHRA before it reaches the Great Britain market, not after.
6. Implement post-market surveillance under Part 4A before launch, not as a retrofit once the device is already selling.

Small and medium manufacturers should budget realistic lead time for approved-body engagement specifically. It’s consistently the step that stretches timelines furthest beyond initial estimates, largely because capacity across UK approved bodies hasn’t scaled as fast as demand for UKCA certification.

How do you keep your registration and compliance current?

Compliance isn’t a one-off milestone. Certain changes legally require an MHRA update: shifts in manufacturer details, changes to intended purpose, or technical modifications to the device itself all trigger notification duties under the same regulations that govern initial registration.

• Monitor legislation.gov.uk directly for consolidated text changes, since secondary commentary often lags behind the actual amendment.
• Track MHRA guidance updates and collections pages, particularly the vigilance guidance, for operational interpretation of new duties.
• Set a periodic internal review cadence, quarterly is reasonable for most manufacturers, so registration details and technical files stay aligned with current obligations rather than drifting out of step.

The 2025 amendment removing specified revocation dates for certain assimilated EU laws is a useful reminder that this framework keeps moving. It doesn’t revert the UK to older EU rules; it builds a distinct UK regulatory base that manufacturers need to watch actively rather than assume is settled.

How should component suppliers support OEM compliance?

Supplier documentation makes or breaks how quickly an OEM’s technical file comes together, and that’s something worth saying plainly rather than dancing around.

Material certificates, batch-level traceability records, and test reports are the documents that actually get used when an approved body starts asking questions. A supplier that can produce a clean certificate matching the exact batch in a customer’s finished device saves that customer weeks of chasing paperwork during an audit. A supplier that can’t do this becomes the bottleneck in someone else’s compliance timeline, which is a bad position for any component manufacturer to be in.

Change control matters just as much as the documents themselves. Robust batch-level traceability and standardised material certificates and test reports reduce time-to-certification for device OEMs preparing UK technical files, but only if suppliers notify customers proactively when a material, process, or specification changes. A silent substitution upstream can quietly invalidate a customer’s existing conformity evidence without either party realising until an audit surfaces it.

Manufacturers sourcing precision components for medical device applications should ask suppliers directly about their traceability and change-notification practices before committing to a supply relationship, not after a compliance issue emerges.

— Alexandra

How Precision Glasses supports your technical file preparation

Specialist suppliers provide precision-engineered glass components for medical device applications, including optical windows, sensor glass, and display glass, accompanied by batch-level traceability and material documentation that regulatory teams need for their technical files.

Where a generic glass supplier hands over a delivery note and little else, Precision Glasses provides material certificates, test reports, and traceable batch records tied directly to the components in your finished device, giving your QA team documentation that stands up under approved-body scrutiny rather than paperwork you have to chase down later. If your device relies on a glass component and you’re assembling technical file evidence for MHRA registration or UKCA certification, our quality standards page details the certification and traceability processes behind every batch, and our technical glass range shows the specifications available for medical applications. Get in touch through the Precision Glasses site to request documentation for your specific component and start building that part of your technical file today.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Sources

• Regulating medical devices in the UK
• The Medical Devices Regulations 2002
• Register medical devices to place on the market

Recommended

• UKCA marking: a compliance guide for GB manufacturers
• Custom glass products for electronics: UK procurement guide